Hi Boris,
I can empathize with you about the onslaught of posters/presentations at ASCO, it can be so head swiveling figuring out where to be and when. At least that is what I recall the most frustrating part being...logistics...it is like you have to have mapped out everything possible you 'might' want to hear/see as they often overlap.
"(Many people assume carfilzomib is more effective than Velcade; Dr. Orlowski's presentation suggests that this assumption often rests on comparisons that aren't really in the "apple-to-apple" category.)"
I agree that the differences are not necessarily about efficacy between the two. Rather, they each have a different mechanism of action due to SAR and that results in possible long-term benefits when it comes to resistance. While this has not been shown definitively, we know that bortezomib is a reversible inhibitor, as is Millenium's new oral PI. However, carfilzomib is irreverisble, along with the new oral PI that Onxy has coming. The only thing we can definitively say at present is that the side effect profile of carfilzomib when it comes to PN is better than bortezomib...but that is a safety vs. efficacy issue.
Did Orlowski provide other details independent of the SAR of the two molecules? The good thing is that although the drugs are both in the same therapeutic class, their chemical moiety differences means we are not seeing a 'class effect' when it comes to PN and we are possibly looking at a better resistance profile and that accounts for carfilzomib working in patients who may have become resistant to bortezomib. Good news, overall.
No, I wasn't referring to the abstract. Landgren is giving an oral presentation. I think, not sure, it is on SPM. and scheduled for today or tonight, possibly.
Forums
Re: ASCO 2012 - Updates From The Meeting
Hi Suzierose,
We're not aware that Dr. Landgren is giving any oral presentations.
Here are the three abstracts that come up under his name (he's not first author on any of them):
http://abstractsearch.asco.org/cgi-bin/ts.pl?index=442064&query=landgren&opt=any&submit.x=0&submit.y=0
The first two are posters, and the last is an e-abstract (published online only, not to be presented at the meeting).
We're also not aware of any myeloma-related talks about secondary cancers, just several posters.
Let us know if you find one that we possibly missed while perusing the schedule.
We're not aware that Dr. Landgren is giving any oral presentations.
Here are the three abstracts that come up under his name (he's not first author on any of them):
http://abstractsearch.asco.org/cgi-bin/ts.pl?index=442064&query=landgren&opt=any&submit.x=0&submit.y=0
The first two are posters, and the last is an e-abstract (published online only, not to be presented at the meeting).
We're also not aware of any myeloma-related talks about secondary cancers, just several posters.
Let us know if you find one that we possibly missed while perusing the schedule.
-
Julie Shilane - Name: Julie Shilane, Beacon Staff
Re: ASCO 2012 - Updates From The Meeting
Hi Julie!
Thanks for the reply. Landgren allows the fellows on his team (Roschewski / Kwok / Korde / Manasanch) to be the first/lead author(s). It appears to be a new trend in the clinical literature with a lot of the well-established scientists, where the most esteemed & well published scientist is listed last and his team is listed first.
Perhaps, I misunderstood him last Thurs, but I believed he said he was providing an oral presentation..
Thanks for checking.
Thanks for the reply. Landgren allows the fellows on his team (Roschewski / Kwok / Korde / Manasanch) to be the first/lead author(s). It appears to be a new trend in the clinical literature with a lot of the well-established scientists, where the most esteemed & well published scientist is listed last and his team is listed first.
Perhaps, I misunderstood him last Thurs, but I believed he said he was providing an oral presentation..
Thanks for checking.
-
suzierose - Name: suzierose
- When were you/they diagnosed?: 2 sept 2011
Re: ASCO 2012 - Updates From The Meeting
Hi Suzierose!
My recollection is that Dr. Orlowski didn't emphasize very much differences in the mechanism of action of carfilzomib and Velcade.
He also seems to place less emphasis than one might expect on potential differences in the side effect profiles of the two drugs. He pointed out a couple of times that comparisons on that front really need to be made using side effect data for Velcade administered subcutaneously and once a week, which is a dosing regimen that is becoming more and more common, and which appears to reduce Velcade's side effects with little effect on efficacy.
In the end, it seems like the main area where Dr. Orlowski sees a potential difference between the two drugs is in their depth of response. Carfilzomib, he concludes, may generate deeper responses (more complete and stringent complete responses) than Velcade.
Just as a reminder, Dr. Orlowski has made his presentation available for download and viewing as a courtesy to Beacon readers. Here is a link to the slide deck: http://bit.ly/KYUS7A .
My recollection is that Dr. Orlowski didn't emphasize very much differences in the mechanism of action of carfilzomib and Velcade.
He also seems to place less emphasis than one might expect on potential differences in the side effect profiles of the two drugs. He pointed out a couple of times that comparisons on that front really need to be made using side effect data for Velcade administered subcutaneously and once a week, which is a dosing regimen that is becoming more and more common, and which appears to reduce Velcade's side effects with little effect on efficacy.
In the end, it seems like the main area where Dr. Orlowski sees a potential difference between the two drugs is in their depth of response. Carfilzomib, he concludes, may generate deeper responses (more complete and stringent complete responses) than Velcade.
Just as a reminder, Dr. Orlowski has made his presentation available for download and viewing as a courtesy to Beacon readers. Here is a link to the slide deck: http://bit.ly/KYUS7A .
-
Boris Simkovich - Name: Boris Simkovich
Founder
The Myeloma Beacon
Re: ASCO 2012 - Updates From The Meeting
The Beacon has received Dr. Vij's presentation about pomalidomide that he gave at yesterday's morning ASCO session. He is making them available for viewing by the Beacon's readers. They can be viewed here: http://bit.ly/LghIrS .
-
Maike Haehle - Name: Maike Haehle
Associate Publisher
The Myeloma Beacon
Re: ASCO 2012 - Updates From The Meeting
Good morning everyone,
Today is the fourth day of the 2012 ASCO annual meeting in Chicago. It's also the last day with a substantial number of myeloma-related presentations.
And substantial is the right word.
There will be a set of oral presentations this morning about monoclonal antibody drugs being developed as potential treatments for multiple myeloma. Many of you have heard of elotuzumab, which is probably the best known of those drugs. But there also will be presentations about siltuximab and daratumumab.
Then, this afternoon, there will be a poster session where a large number of myeloma-related research results will be made public.
We'll be covering the key research findings from both these sessions in another series of ASCO 2012 multiple myeloma daily updates.
Remember, you can see all the Beacon's ASCO 2012 news articles at this page:
https://myelomabeacon.org/tag/asco-2012-meeting/
Today is the fourth day of the 2012 ASCO annual meeting in Chicago. It's also the last day with a substantial number of myeloma-related presentations.
And substantial is the right word.
There will be a set of oral presentations this morning about monoclonal antibody drugs being developed as potential treatments for multiple myeloma. Many of you have heard of elotuzumab, which is probably the best known of those drugs. But there also will be presentations about siltuximab and daratumumab.
Then, this afternoon, there will be a poster session where a large number of myeloma-related research results will be made public.
We'll be covering the key research findings from both these sessions in another series of ASCO 2012 multiple myeloma daily updates.
Remember, you can see all the Beacon's ASCO 2012 news articles at this page:
https://myelomabeacon.org/tag/asco-2012-meeting/
Re: ASCO 2012 - Updates From The Meeting
hI Maike and Boris...thanks for the interesting and vital updates on recent studies involving new chemotherapy agents. I was interested to see on the slide presentation about pomalidomide, Maike, that one of the investigators works at the Tom Baker Centre, Calgary...Dr. N. Bahliss. Our walk/run on July 28 raises funds for the research and clinical trials done through his and Dr. Neri's lab. They have a wonderful team of dedicated researchers.. Check out our local support group for more info (SAMPS).
As ever , am learning lots more about myeloma through the Beacon's good articles...thanks so much again!!
As ever , am learning lots more about myeloma through the Beacon's good articles...thanks so much again!!
-
Nancy Shamanna - Name: Nancy Shamanna
- Who do you know with myeloma?: Self and others too
- When were you/they diagnosed?: July 2009
Re: ASCO 2012 - Updates From The Meeting
Dr. Chanan-Khan also made his presentation discussing Treanda, panobinostat, and obatoclax available to the Beacon's readers. His slides can be viewed here: http://bit.ly/KKepd6 .
-
Julie Shilane - Name: Julie Shilane, Beacon Staff
Re: ASCO 2012 - Updates From The Meeting
Thank's Beacon Staff for the slides!!
and timely updates....whooosh...you guys are working fast, hard and furious!!
While the slide links for Vij and Khan work...the one for Orlowski hasn't.
and timely updates....whooosh...you guys are working fast, hard and furious!!
While the slide links for Vij and Khan work...the one for Orlowski hasn't.
-
suzierose - Name: suzierose
- When were you/they diagnosed?: 2 sept 2011
Re: ASCO 2012 - Updates From The Meeting
Hi Suzierose!
The Orlowski slides are in Powerpoint format. In some browsers, they will open fine because the browser will automatically start Powerpoint up. In others, you'll have to download the file, save it, and then open it up separately with Powerpoint or another program that can read Powerpoint files.
We left the slides in Powerpoint format because (a) Dr. Orlowski was okay with that, and (b) it gives everyone easier access to the raw information in the slides.
The Orlowski slides are in Powerpoint format. In some browsers, they will open fine because the browser will automatically start Powerpoint up. In others, you'll have to download the file, save it, and then open it up separately with Powerpoint or another program that can read Powerpoint files.
We left the slides in Powerpoint format because (a) Dr. Orlowski was okay with that, and (b) it gives everyone easier access to the raw information in the slides.
-
Boris Simkovich - Name: Boris Simkovich
Founder
The Myeloma Beacon
26 posts
• Page 2 of 3 • 1, 2, 3